AI Drug Discovery Surges With $2.5B Partnership and $1.7B Takeda-Iambic Deal

Artificial intelligence in drug discovery has moved past the hype cycle and into its most critical phase: proof, with 2026 shaping up as an inflection point after nearly a decade of investment. Multi-billion-dollar partnerships are signaling that large drugmakers are no longer experimenting with AI but outsourcing core discovery workflows to it, including Takeda’s $1.7B+ deal with Iambic Therapeutics and a new AI drug discovery partnership with a contract development and manufacturing organization (CDMO) worth up to $2.5 billion.

The AI drug discovery partnership combines the company’s AI-powered platform with the CDMO’s development, manufacturing and commercialization capabilities. The AI drug discovery company says its platform can generate pre-clinical candidates in 12 to 18 months versus the industry’s typical 2.5 to 4 years. The partnership is expected to help the CDMO expand AI capabilities across its operations while supporting a more integrated path of drug discovery through commercialization.

IB Acquisition announced GNQ entered a two-year joint initiative and marketing agreement with a Fortune 100 technology partner to combine AI drug-discovery and precision medicine solutions. GNQ and the strategic partner will jointly market integrated solutions combining GNQ’s AI platforms with the partner’s consulting, cloud and quantum capabilities. The collaboration covers a global territory, has an initial two-year term and is non-exclusive, with an option to extend by mutual written agreement. IB Acquisition will file a Form S-4 proxy statement/prospectus with the SEC for stockholder review and approval.

Among AI-native biotechs, Earendil Labs raised $787M in financing and expanded multiple Sanofi partnerships, with programs advancing toward clinical stages. Iambic Therapeutics signed a $1.7B+ partnership with Takeda, signaling strong pharma confidence in its platform and pipeline. Enveda achieved unicorn status with a $1B valuation and advanced ENV-294 into Phase II trials. Relation Therapeutics expanded its strategic collaboration with Novartis and advanced its internal pipeline in bone and inflammatory diseases. Micro CRISPR, part of Bilakhia Holdings, is leveraging an integrated platform with access to global clinical, regulatory, and manufacturing infrastructure and has two clinical-stage assets. AQEMIA is expanding its proprietary pipeline following Series A funding, and Terray Therapeutics combines massive proprietary datasets with generative AI to power drug discovery.

With the rise of AI, the data generated in the course of researching and developing molecules has become an asset in its own right. AI-native biotech companies license their models as products and services to life sciences companies, and three structures have emerged for these deals, including the model owner running the analysis and the model owner licensing the model.

Investment activity reflects the momentum. ARK’s largest position addition was 609,643 shares of Recursion Pharmaceuticals, an AI-driven drug discovery company that leverages machine learning to accelerate pharmaceutical development timelines, and the fund increased its holdings in Generate Biomedicines by 63,768 shares. NVIDIA and Nebius will hold an interactive workshop on how the BioNeMo Agent Toolkit is helping developers and life sciences teams build AI-powered workflows for biology, chemistry, drug discovery, and translational research.